Ovarian cancer has one of the highest incidence of gynaecological tumors in China, with more than 57,000 new patients and 27,000 deaths in China each year
.
As research progresses, it has been found that maintenance therapy with PARP inhibitors in ovarian cancer targeting drugs can prolong the remission time after platinum-containing chemotherapy and delay recurrence
.
In March this year, at the annual meeting of the American Society of Gynecologic Oncology (SGO), detailed data from the China Phase III Clinical PME Study on the first-line maintenance therapy of Nirapali, a targeted drug for ovarian cancer, were released, confirming that the use of Nirapalil maintenance therapy could benefit progression-free survival (PFS) in Chinese patients, and that the study also evaluated safer dosing options
.
Studies have confirmed that the ovarian cancer targeting drug Nirapalil has outstanding overall results in the Chinese population
The PRIME study showed that first-line maintenance therapy with the ovarian cancer target drug Nirapalil had a statistically and clinically significant benefit in improving PFS in the entire population compared with placebo, with median progression-free survival of 24.
As the largest Phase III clinical study of first-line PARP inhibitor maintenance therapy for advanced ovarian cancer in China, the results of the PRIME study fill the gap
in the evidence-based medical evidence of PARP inhibitors in the first-line maintenance treatment of ovarian cancer in China.
Individualized dosing regimens for the ovarian cancer target drug Nirapalil improve drug safety
The PRIME study also prospectively assessed the safety
of newly diagnosed patients with advanced ovarian cancer receiving individualized starting dose of nirapalil maintenance therapy after a response to first-line platinum-containing chemotherapy.
Indications for first-line whole-population maintenance therapy in Nirapali are on the medical insurance list, and more ovarian cancer patients are expected to benefit
The birth and clinical application of PARP inhibitors has made "surgery + chemotherapy + PARP inhibitor maintenance therapy" a new "gold standard" in the treatment of patients with advanced ovarian cancer
.
At the end of 2020, Nirapalil entered the national medical insurance drug list for the first time, and the indication was maintenance therapy
for platinum-sensitive recurrent ovarian cancer.
At the end of 2021, after Neirapali has once again gone through medical insurance negotiations, a new first-line whole-population maintenance treatment indication has been added, that is, whether ovarian cancer patients have BRCA gene mutations or not, the use of Nirapali first-line maintenance therapy can be reimbursed, filling the gap
that BRCA unmutated patients cannot be reimbursed by medical insurance.
The clinical data of Nirapalil in the PRIME study for the ovarian cancer target drug undoubtedly brings more hope to Chinese ovarian cancer patients, and it is believed that with the help of medical insurance, patients can effectively reduce the economic burden
while getting better treatment.
Ovarian cancer has one of the highest incidence of gynaecological tumors in China, with more than 57,000 new patients and 27,000 deaths in China each year
.
As research progresses, it has been found that maintenance therapy with PARP inhibitors in ovarian cancer targeting drugs can prolong the remission time after platinum-containing chemotherapy and delay recurrence
.
In March this year, at the annual meeting of the American Society of Gynecologic Oncology (SGO), detailed data from the China Phase III Clinical PME Study on the first-line maintenance therapy of Nirapali, a targeted drug for ovarian cancer, were released, confirming that the use of Nirapalil maintenance therapy could benefit progression-free survival (PFS) in Chinese patients, and that the study also evaluated safer dosing options
.
Studies have confirmed that the ovarian cancer targeting drug Nirapalil has outstanding overall results in the Chinese population
The PRIME study showed that first-line maintenance therapy with the ovarian cancer target drug Nirapalil had a statistically and clinically significant benefit in improving PFS in the entire population compared with placebo, with median progression-free survival of 24.
As the largest Phase III clinical study of first-line PARP inhibitor maintenance therapy for advanced ovarian cancer in China, the results of the PRIME study fill the gap
in the evidence-based medical evidence of PARP inhibitors in the first-line maintenance treatment of ovarian cancer in China.
Individualized dosing regimens for the ovarian cancer target drug Nirapalil improve drug safety
The PRIME study also prospectively assessed the safety
of newly diagnosed patients with advanced ovarian cancer receiving individualized starting dose of nirapalil maintenance therapy after a response to first-line platinum-containing chemotherapy.
Indications for first-line whole-population maintenance therapy in Nirapali are on the medical insurance list, and more ovarian cancer patients are expected to benefit
The birth and clinical application of PARP inhibitors has made "surgery + chemotherapy + PARP inhibitor maintenance therapy" a new "gold standard" in the treatment of patients with advanced ovarian cancer
.
In order to make standard treatment more ovarian cancer patients, in recent years, under the impetus of the policy of benefiting the people, PARP inhibitors have gradually occupied a place
in the medical insurance list.
At the end of 2020, Nirapalil entered the national medical insurance drug list for the first time, and the indication was maintenance therapy
for platinum-sensitive recurrent ovarian cancer.
At the end of 2021, after Neirapali has once again gone through medical insurance negotiations, a new first-line whole-population maintenance treatment indication has been added, that is, whether ovarian cancer patients have BRCA gene mutations or not, the use of Nirapali first-line maintenance therapy can be reimbursed, filling the gap
that BRCA unmutated patients cannot be reimbursed by medical insurance.
After reimbursement, the out-of-pocket cost per box in many areas is about 1,000 yuan or even less, and the average monthly out-of-pocket cost of treatment has been greatly reduced, and life-saving drugs have become more intimate
.
The clinical data of Nirapalil in the PRIME study for the ovarian cancer target drug undoubtedly brings more hope to Chinese ovarian cancer patients, and it is believed that with the help of medical insurance, patients can effectively reduce the economic burden
while getting better treatment.
Ovarian cancer has one of the highest incidence of gynaecological tumors in China, with more than 57,000 new patients and 27,000 deaths in China each year
.
Although advanced ovarian cancer can be relieved by initial platinum-containing chemotherapy, most patients inevitably face relapse and gradually become resistant to platinum-based drugs as the number of recurrences increases
.
As research progresses, it has been found that maintenance therapy with PARP inhibitors in ovarian cancer targeting drugs can prolong the remission time after platinum-containing chemotherapy and delay recurrence
.
Especially for patients with newly diagnosed advanced ovarian cancer, the PARP inhibitor Nirapalil, which can ignore the patient's biomarker status, has attracted much attention
.
In March this year, at the annual meeting of the American Society of Gynecologic Oncology (SGO), detailed data from the China Phase III Clinical PME Study on the first-line maintenance therapy of Nirapali, a targeted drug for ovarian cancer, were released, confirming that the use of Nirapalil maintenance therapy could benefit progression-free survival (PFS) in Chinese patients, and that the study also evaluated safer dosing options
.
Studies have confirmed that the ovarian cancer targeting drug Nirapalil has outstanding overall results in the Chinese population
Studies have confirmed that the ovarian cancer targeting drug Nirapalil has outstanding overall results in Chinese and Chinese populations
The PRIME study showed that first-line maintenance therapy with the ovarian cancer target drug Nirapalil had a statistically and clinically significant benefit in improving PFS in the entire population compared with placebo, with median progression-free survival of 24.
8 months in the Nirapalil group compared with 8.
3 months
in the placebo group, regardless of biomarker status.
In patients without BRCA mutation, the median PFS was 19.
3 months, compared to 8.
3 months in the placebo group, and the empty window period (period of discontinuation observation) was up to 11 months
.
As the largest Phase III clinical study of first-line PARP inhibitor maintenance therapy for advanced ovarian cancer in China, the results of the PRIME study fill the gap
in the evidence-based medical evidence of PARP inhibitors in the first-line maintenance treatment of ovarian cancer in China.
Individualized dosing regimens for the ovarian cancer target drug Nirapalil improve drug safety
Individualized dosing regimens for the ovarian cancer target drug Nirapalil improve drug safety
The PRIME study also prospectively assessed the safety
of newly diagnosed patients with advanced ovarian cancer receiving individualized starting dose of nirapalil maintenance therapy after a response to first-line platinum-containing chemotherapy.
Therefore, in this study, Chinese patients used an individualized dosing regimen of baseline body weight and baseline platelet count, and only those with a baseline body weight of ≥ 77 kg and a baseline platelet count of ≥ 150000/μL were only given a starting dose of 300 mg qd, and the rest were started
at 200 mg qd.
The final results showed that the proportion of patients discontinuing treatment due to adverse events was the lowest of all PARP inhibitors used in the phase III clinical study of
first-line maintenance therapy for ovarian cancer.
Individualized doses of administration reduce the incidence
of hematological adverse events compared to previous fixed starting doses.
This also revalidates the tolerability of Nirapali in maintenance therapy in the study population, which greatly encourages the confidence of
ovarian cancer patients to continue treatment.
Indications for first-line whole-population maintenance therapy in Nirapali are on the medical insurance list, and more ovarian cancer patients are expected to benefit
Indications for first-line whole-population maintenance therapy in Nirapali are on the medical insurance list, and more ovarian cancer patients are expected to benefit
The birth and clinical application of PARP inhibitors has made "surgery + chemotherapy + PARP inhibitor maintenance therapy" a new "gold standard" in the treatment of patients with advanced ovarian cancer
.
In order to make standard treatment more ovarian cancer patients, in recent years, under the impetus of the policy of benefiting the people, PARP inhibitors have gradually occupied a place
in the medical insurance list.
At the end of 2020, Nirapalil entered the national medical insurance drug list for the first time, and the indication was maintenance therapy
for platinum-sensitive recurrent ovarian cancer.
At the end of 2021, after Neirapali has once again gone through medical insurance negotiations, a new first-line whole-population maintenance treatment indication has been added, that is, whether ovarian cancer patients have BRCA gene mutations or not, the use of Nirapali first-line maintenance therapy can be reimbursed, filling the gap
that BRCA unmutated patients cannot be reimbursed by medical insurance.
After reimbursement, the out-of-pocket cost per box in many areas is about 1,000 yuan or even less, and the average monthly out-of-pocket cost of treatment has been greatly reduced, and life-saving drugs have become more intimate
.
The clinical data of Nirapalil in the PRIME study for the ovarian cancer target drug undoubtedly brings more hope to Chinese ovarian cancer patients, and it is believed that with the help of medical insurance, patients can effectively reduce the economic burden
while getting better treatment.
